Compare · NMRA vs RLMD

NMRA vs RLMD

Side-by-side comparison of Neumora Therapeutics Inc. (NMRA) and Relmada Therapeutics Inc. (RLMD): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both companies sit in the Health Care sector. NMRA focuses on Biotechnology: Biological Products (No Diagnostic Substances), while RLMD focuses on Biotechnology: Pharmaceutical Preparations.
  • RLMD is the larger of the two at $321.2M, about 5.2x NMRA ($61.9M).
  • RLMD has been more active in the news (8 items in the past 4 weeks vs 5 for NMRA).
  • NMRA has more recent analyst coverage (23 ratings vs 14 for RLMD).
MetricNMRARLMD
Company
Neumora Therapeutics Inc.
Relmada Therapeutics Inc.
Price
-
-
Market cap
$61.9M
$321.2M
1M return
-
-
1Y return
-
-
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Exchange
NASDAQ
NASDAQ
IPO
2023
News (4w)
5
8
Recent ratings
23
14
RLMD

Relmada Therapeutics Inc.

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing drugs to treat central nervous system (CNS) diseases and other disorders in the United States. Its lead product candidate, d-Methadone, an oral agent, which is in Phase II clinical trial for the treatment of depression, neuropathic pain, and other potential CNS pathological conditions. The company is also developing LevoCap ER, an abuse resistant, sustained release dosage form of the opioid analgesic levorphanol; BuTab, an oral dosage form of the opioid analgesic buprenorphine; and MepiGel, an orphan drug designated topical formulation of the local anesthetic mepivacaine. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in New York, New York.

Latest NMRA

Latest RLMD